No abstract

Patients with psoriasis are at an increased risk of metabolic syndrome (MetS); however, a systematic analysis of its global prevalence has not been performed to date. Here, we performed a systematic review and meta‐analysis to assess the prevalence of MetS among patients with psoriasis. We searched five databases from inception through September 2021 and used the Agency for Healthcare Research and Quality (AHRQ) and Newcastle–Ottawa Scale (NOS) tools to assess observational study quality. Stata SE 15.1 was used to perform the data analysis. Subgroup, meta‐regression and sensitivity analyses were used to evaluate interstudy heterogeneity. Publication bias was evaluated using Egger's and Begg's linear tests. The global prevalence of MetS in patients with psoriasis was 32% (95% confidence interval [CI], 0.26–0.38). The prevalence in adults was 32% (95% CI, 0.29–0.36), while that in children and adolescents was 9% (95% CI, 0.00–0.18). Latin America had the highest prevalence of 47% (95% CI, 0.43–0.51), whereas North America had the lowest prevalence of 26% (95% CI, 0.16–0.37). Patients with psoriasis vulgaris (29%; 95% CI, 0.23–0.35) or severe psoriasis (37%; 95% CI, 0.27–0.46) had a higher prevalence of MetS than those with other psoriasis types. These findings suggest that MetS should be appropriately recognized and managed in patients with psoriasis. More population‐based prospective observational studies are required to elucidate the mechanisms underlying the coexistence of MetS in patients with psoriasis.

Background We discovered that vitiligo was associated with sexual dysfunction in clinical diagnosis and treatment; however, no further analysis had been performed due to a lack of data. Objective This study aimed to clarify the relationship between vitiligo and sexual dysfunction. Methods We searched six databases (PubMed, Embase, Cochrane, China National Knowledge Infrastructure, China Science and Technology Journal, and Wanfang Data Knowledge Service Platform) for nearly 40 years. Results According to the search strategy, 91 relevant studies were retrieved, of which 4 were included in the analysis. The Arizona Sexual Experience Scale (ASEX) score (mean difference [MD] 4.96, 95% confidence interval [CI] 2.78–7.13, p < 0.00001) was higher in the vitiligo group than in the control group. The Arabic version of the Female Sexual Function Index (AVFSFI) score (mean difference [MD] − 3.40, 95% confidence interval [CI] − 5.49 to −1.31, p = 0.001) was lower in the vitiligo group than in the control group. Conclusions Patients with vitiligo were found to be at greater risk of sexual dysfunction. Moreover, the association between vitiligo and sexual dysfunction was stronger in women than in men. Key Messages Patients with vitiligo were found to be at greater risk of sexual dysfunction. The association between vitiligo and sexual dysfunction was stronger in women than in men.